Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ADMA Adma Biologics Inc
- Stocks
- Healthcare
- NASDAQ: ADMA
Price (delayed)
$19.69
Market cap
$4.7B
P/E Ratio
22.38
Dividend/share
N/A
EPS
$0.88
Enterprise value
$4.7B
ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at
Highlights
The equity has surged by 143% year-on-year and by 7% since the previous quarter
The gross profit has soared by 117% YoY and by 10% from the previous quarter
Key stats
What are the main financial stats of ADMA
Market
Valuations
Earnings
Shares outstanding
238.73M
Market cap
$4.7B
Enterprise value
$4.7B
Price to earnings (P/E)
22.38
Price to book (P/B)
12.53
Price to sales (P/S)
10.19
EV/EBIT
30.76
EV/EBITDA
29.25
EV/Sales
10.24
Revenue
$459.38M
Gross profit
$241.54M
Operating income
$152.04M
Net income
$206.77M
EBIT
$152.9M
EBITDA
$160.8M
Free cash flow
$90.64M
Per share
Balance sheet
Liquidity
EPS
$0.88
EPS diluted
$0.85
Free cash flow per share
$0.38
Book value per share
$1.57
Revenue per share
$1.93
TBVPS
$2.13
Total assets
$510.57M
Total liabilities
$137.15M
Debt
$73.72M
Equity
$373.42M
Working capital
$298.32M
Debt to equity
0.2
Current ratio
6.58
Quick ratio
3.2
Net debt/EBITDA
0.01
Margins
Efficiency
Dividend
EBITDA margin
35%
Gross margin
52.6%
Net margin
45%
Operating margin
33.1%
Return on assets
46.8%
Return on equity
72.4%
Return on invested capital
38.6%
Return on capital employed
33.5%
Return on sales
33.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ADMA stock price
How has the Adma Biologics stock price performed over time
Intraday
2.55%
1 week
-1.45%
1 month
-7.25%
1 year
117.33%
YTD
14.81%
QTD
-0.76%
Financial performance
How have Adma Biologics's revenue and profit performed over time
Revenue
$459.38M
Gross profit
$241.54M
Operating income
$152.04M
Net income
$206.77M
Gross margin
52.6%
Net margin
45%
The gross profit has soared by 117% YoY and by 10% from the previous quarter
Adma Biologics's operating margin has surged by 112% YoY
ADMA's revenue has surged by 62% year-on-year and by 8% since the previous quarter
ADMA's gross margin is up by 34% YoY and by 2.1% QoQ
Price vs fundamentals
How does ADMA's price correlate with its fundamentals
Growth
What is Adma Biologics's growth rate over time
Valuation
What is Adma Biologics stock price valuation
P/E
22.38
P/B
12.53
P/S
10.19
EV/EBIT
30.76
EV/EBITDA
29.25
EV/Sales
10.24
The price to earnings (P/E) is 52% lower than the last 4 quarters average of 46.5
The EPS has grown by 3.5% since the previous quarter
The equity has surged by 143% year-on-year and by 7% since the previous quarter
The price to book (P/B) is 105% higher than the 5-year quarterly average of 6.1 but 14% lower than the last 4 quarters average of 14.5
ADMA's price to sales (P/S) is 96% higher than its 5-year quarterly average of 5.2 and 2.9% higher than its last 4 quarters average of 9.9
ADMA's revenue has surged by 62% year-on-year and by 8% since the previous quarter
Efficiency
How efficient is Adma Biologics business performance
ADMA's ROE is down by 16% QoQ
The company's return on assets fell by 4.9% QoQ
The company's return on invested capital rose by 4.3% QoQ
Dividends
What is ADMA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ADMA.
Financial health
How did Adma Biologics financials performed over time
ADMA's quick ratio has soared by 79% YoY and by 16% QoQ
Adma Biologics's total assets has increased by 46% YoY and by 4.5% from the previous quarter
The company's debt is 80% lower than its equity
The equity has surged by 143% year-on-year and by 7% since the previous quarter
Adma Biologics's debt to equity has shrunk by 77% YoY and by 4.8% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.